aTyr Pharma (ATYR) Stock Price, News & Analysis

Company Overview

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas.

Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.

Key Stats

• Today's Range: $5.08 to $5.44
• 50-Day Range: $4.66 to $6.61
• 52-Week Range: $1.67 to $7.29
• Volume: 4.05 million shs
• Average Volume: 2.62 million shs
• Market Capitalization: $513.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.25
• Consensus Rating: Buy

aTyr Pharma Stock Analysis - MarketRank™

aTyr Pharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 590th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Buy

Consensus Rating

aTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

aTyr Pharma has a consensus price target of $23.25, representing about 344.6% upside from its current price of $5.23.

Amount of Analyst Coverage

aTyr Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for aTyr Pharma are expected to grow in the coming year, from ($0.91) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of aTyr Pharma is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of aTyr Pharma is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

aTyr Pharma has a P/B Ratio of 6.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.43% of the float of aTyr Pharma has been sold short.

Short Interest Ratio / Days to Cover

aTyr Pharma has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in aTyr Pharma has recently increased by 10.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

aTyr Pharma does not currently pay a dividend.

Dividend Growth

aTyr Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.43% of the float of aTyr Pharma has been sold short.

Short Interest Ratio / Days to Cover

aTyr Pharma has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in aTyr Pharma has recently increased by 10.35%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.75

News Sentiment

aTyr Pharma has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for aTyr Pharma this week, compared to 3 articles on an average week.

Search Interest

37 people have searched for ATYR on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.

MarketBeat Follows

Only 12 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, aTyr Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of aTyr Pharma is held by insiders.

Percentage Held by Institutions

61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATYR Stock Analysis - Frequently Asked Questions

How have ATYR shares performed this year?

aTyr Pharma's stock was trading at $3.62 at the beginning of the year. Since then, ATYR shares have increased by 44.5% and is now trading at $5.23.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:ATYR) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04.

Who are aTyr Pharma's major shareholders?

Top institutional shareholders of aTyr Pharma include Octagon Capital Advisors LP (3.90%), Geode Capital Management LLC (2.36%), Invesco Ltd. (0.61%) and Marshall Wace LLP (0.52%). Insiders that own company stock include Paul Schimmel, Jill Marie Broadfoot, Nancy Denyes and Jane A Gross.
View institutional ownership trends.

How do I buy shares of aTyr Pharma?

Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Dare Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATYR
• Previous Symbol: NASDAQ:ATYR
• CIK: 1339970
• Web: N/A
• Phone: (858) 731-8389
• Fax: 858-731-8394
• Employees: 53
• Year Founded: N/A

Price Target and Rating

• Average Price Target for aTyr Pharma: $23.25
• High Price Target: $35.00
• Low Price Target: $16.00
• Potential Upside/Downside: +338.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.02 million
• Net Margins: N/A
• Pretax Margin: -27,243.40%
• Return on Equity: -93.69%
• Return on Assets: -68.83%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.63
• Quick Ratio: 5.63

Sales & Book Value

• Annual Sales: $230 thousand
• Price / Sales: 2,260.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 6.39

Miscellaneous

• Outstanding Shares: 97,990,000
• Free Float: 94,361,000
• Market Cap: $519.84 million
• Optionable: Optionable
• Beta: 1.01